Filtered By:
Therapy: Chemotherapy
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1019 results found since Jan 2013.
A US-based national surveillance study for the susceptibility and epidemiology of < em > Clostridioides difficile < /em > isolates with special reference to ridinilazole: 2020-2021
Antimicrob Agents Chemother. 2023 Sep 20:e0034923. doi: 10.1128/aac.00349-23. Online ahead of print.ABSTRACTWe have previously reported on the susceptibility and epidemiology of Clostridioides difficile isolates from six geographically dispersed medical centers in the United States. This current survey was conducted with isolates collected in 2020-2021 from six geographically dispersed medical centers in the United States, with specific attention to susceptibility to ridinilazole as well as nine comparators. C. difficile isolates or stools from patients with C. difficile antibiotic-associated diarrhea were collected and re...
Source: Antimicrobial Agents and Chemotherapy - September 20, 2023 Category: Microbiology Authors: D R Snydman L A McDermott C M Thorpe E J C Goldstein A N Schuetz S Johnson D N Gerding L Gluck D Bourdas K C Carroll C K Lancaster K W Garey Q Wang S T Walk E Duperchy Source Type: research
Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States
CONCLUSION: In both unadjusted and adjusted analyses, there were no differences in the clinical outcomes observed among patients with a/mNSCLC in this study. This study found that initiating chemotherapy with an early switch to targeted therapy (within 56 days) of receiving biomarker positive results may be an acceptable strategy for a patient for whom immediate care is needed.PMID:37717466 | DOI:10.1016/j.ctarc.2023.100761
Source: Cell Research - September 17, 2023 Category: Cytology Authors: Lisa M Hess Patrick Peterson Tomoko Sugihara Naleen Raj Bhandari Peter M Krein Anthony Sireci Source Type: research
Symptom Clusters in Patients With Colorectal Cancer and Diabetes Over Time
Oncol Nurs Forum. 2023 Jun 15;50(4):475-485. doi: 10.1188/23.ONF.475-485.ABSTRACTOBJECTIVES: To examine symptoms and symptom clusters in patients with colorectal cancer (CRC) with or without diabetes at three key periods (0-6 months, 12-18 months, and 24-30 months) post-initial chemotherapy.SAMPLE & SETTING: Patients with CRC from a cancer center in the midwestern United States between January 2007 and December 2017.METHODS & VARIABLES: Eight of the most common symptoms (fatigue, gastrointestinal issues, depression, anxiety, peripheral neuropathy, physical function, cognition, and sleep disturbance) reported by pat...
Source: Oncology Nursing Forum - September 7, 2023 Category: Nursing Authors: Susan Storey Xiao Luo Jie Ren Kun Huang Diane Von Ah Source Type: research
Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer
Int Rev Cell Mol Biol. 2023;380:173-210. doi: 10.1016/bs.ircmb.2023.03.012. Epub 2023 Apr 12.ABSTRACTProstate cancer is the second leading cause of cancer death among men in the United States. Depending upon the histopathological subtypes of prostate cancers, various therapeutic options, such as androgen deprivation therapy (ADT), androgen receptor signaling inhibitors (ARSI), immunotherapy, and chemotherapy, are available to treat prostate cancer. While these therapeutics are effective in the initial stages during treatments, the tumors subsequently develop resistance to these therapies. Despite all the progress made so f...
Source: Mol Biol Cell - September 1, 2023 Category: Molecular Biology Authors: Priti Roy Kamaleshwar P Singh Source Type: research
